EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Potential breakthrough technology for stem-cell based bone replacement

NEW YORK, May 22, 2019 /PRNewswire/ — EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for ramus continuity defects in the mandible. The ramus is a key component of the jaw bone which attaches to the muscles associated with chewing.

EB-CMF is a living anatomically correct bone graft manufactured from a patient’s own adipose derived stem cells. This eliminates the need to harvest bone from a patient’s body, potentially reducing pain, surgical and hospitalization time while creating a precision fit with the defect.

“We are proud of the work that has been put into this IND, and are grateful to our entire team, as well as all our investors, consultants, and champions in the field who have made this possible,” commented Dr. Nina Tandon, CEO and Co-Founder of EpiBone. “Our technology has the potential to change the field of skeletal reconstruction as we know it. Our goal is to help as many patients as we can to regain optimal form and function, in the most seamless, long-term, and natural way possible.”

The Phase 1/2 clinical study will evaluate the EB-CMF product directly in patients with mandibular ramus continuity defects which require reconstruction. In addition to the primary safety of EB-CMF, the study is also designed to demonstrate the effectiveness of EB-CMF in bone reconstruction in addition to integration with the native tissue. The company expects to enroll 6 patients in this study. The company hopes this study will inform the exploration of other potential indications for other facial reconstructive surgeries requiring bone grafts, as well as studies for cartilage replacement in the knee, and other areas of the body.

About EpiBone

EpiBone, Inc. is privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of a patient’s own cells to create living solutions that become a seamless part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.

For more information, please visit: https://www.epibone.com/

Disclaimer

This communication contains forward-looking statements which can generally can be identified by words such as “plans,” “change,” “will,” “following”, “strengthening,” “developing, the negative of these words and similar words and expressions, which are based on EpiBone’s current expectations, assumptions, estimates and projections about its business, technology, product development and industry. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and include, without limitation, EpiBone’s ability to (1) adequately protect or enforce its intellectual property rights, (2) develop and commercialize new products and technologies on a timely basis (or at all), (3) risks associated with acquisitions and strategic investments and (4) attract and retain qualified personnel. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. Additionally, this communication does not constitute an offer to sell or a solicitation of an offer to buy securities.

View original content to download multimedia:http://www.prnewswire.com/news-releases/epibone-inc-receives-fda-clearance-to-commence-its-first-in-human-phase-12-trial-of-its-bone-product-eb-cmf-300854412.html

SOURCE EpiBone, Inc.

Staff

Recent Posts

Panacea Healthcare Solutions to Host Webinar on Aligning Strategic Pricing and Payer Contract Modeling to Maximize Financial Performance

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- Panacea Healthcare Solutions, a leading provider of financial,…

31 minutes ago

Uniting to Improve Wellbeing and Social Capital: Bipartisan Solutions to End Social Isolation and Loneliness in America

A Capitol Hill Convening to Advance Cross-Sector Strategies that Rebuild Human Connection and Strengthen Communities WASHINGTON,…

31 minutes ago

Smart Healthcare Is Taking Over. Here’s Where the Money’s Headed

Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025…

31 minutes ago

LeanTaaS Launches iQueue for Surgical Clinics, Delivering the Industry’s First End‑to‑End Surgical Coordination Platform

Unveiled live at Transform, LeanTaaS' hospital operations summit, the new product embeds key case building, managing,…

31 minutes ago

Salimetrics CoreLab+ Expands Access to Dried Blood Spot Testing for Researchers

Salimetrics, a leading provider of biospecimen collection and salivary bioscience testing methods, is excited to…

31 minutes ago

Nexus IT Secures $60M Investment to Accelerate Founder-Led, Values-Driven MSP/MSSP Expansion

New investment from Metropolitan Partners Group positions Nexus IT to lead a values-aligned M&A model reshaping the managed services landscape. SALT LAKE CITY, June 10, 2025 /PRNewswire/ -- Nexus IT,…

31 minutes ago